EN DE
Watch Vivesto AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vivesto AB (VIVE) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Vivesto AB stock SEK 3.76, price SEK 7.20, that is 47.8% below the price, quality 49 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0000722365

VA Vivesto AB logo Thin data Nov 13, 2026

Vivesto AB

VIVE · ST

Far too expensive (fair value 48% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Quality 49/100 
Fair value kr 3.76 · Strongly overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −20.4 %/yr in SEK) 
Negative free cash flow 
Trails peers (1/5) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Vivesto AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 260.94 kr 6.82 Fair Value kr 3.76 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range kr 6.82 – kr 260.94 · fair‑value band kr 2.82 – kr 4.70 · the kr 7.20 price screens above the kr 3.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.

Follow Vivesto in your weekly email

Every Wednesday you see whether Vivesto is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma.

Show moreShow less

The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer.

The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.

Stock analysis

Vivesto AB (VIVE) currently trades at kr 7.20, while our estimate is kr 3.76, 48% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 2.82 (bear) to kr 4.70 (bull), the price of kr 7.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Vivesto AB reported revenue of 0 SEK in FY2025 versus 26.2M SEK in FY2021. Reported net income was −34.1M SEK in FY2025.

Key figures

Market cap 79.7M SEK (≈ $7.9M) Micro · EPS (TTM) kr −4.12 · Return on equity −21.1% · Return on assets (EBIT) −46.4% (5-year average) · Operating margin −393,313% · Revenue (TTM) 8.0K SEK · Revenue growth (YoY) +223% · Free cash flow −43.8M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 65% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −48%, VIVE screens richer than that median.

Fair Value

Bear kr 2.82 Fair Value kr 3.76 Bull kr 4.70
Price kr 7.20 · Downside -47.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−96.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−82.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.4%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+88.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,273.1% (2017) → −35,144.7% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

VIVE screens overvalued: fair value 48% below the price. Compare with Merck KGaA →

Compare Vivesto AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −47.8% · Bottom 25%
Profitability
Return on assets −22.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 222.7% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.64× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs VIVE
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.07 ¥53.04 +10% vs VIVE
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,880 ₹1,983 +5% vs VIVE
Haleon plc HLN $9.17 $8.62 −6% vs VIVE
Merck KGaA MRK €149.60 €108.83 −27% vs VIVE
Galderma Group GALD CHF 191.40 CHF 111.92 −42% vs VIVE
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs VIVE
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs VIVE
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs VIVE
Divi's Laboratories Limited DIVISLAB ₹11,442 ₹1,567 −86% vs VIVE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vivesto AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vivesto AB Fair Value". https://www.fairvalue-calculator.com/stock/VIVE

Frequently asked questions

Is Vivesto AB (VIVE) overvalued or undervalued?
As of Nov 13, 2026, our estimate of fair value is kr 3.76 versus a price of kr 7.20, about 48% lower (overvalued).
What is the fair value of VIVE?
Our estimate for Vivesto AB is kr 3.76 (as of Nov 13, 2026), built from audited fundamentals. The current price: kr 7.20.
What is the quality score of VIVE?
Vivesto AB has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vivesto AB (VIVE)?
Our calculated price target is the estimate of kr 3.76 (as of Nov 13, 2026). Cautious scenario kr 2.82, optimistic scenario kr 4.70. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Vivesto AB stock forecast for 2026?
Our estimate puts fair value at kr 3.76, about 48% lower versus a price of kr 7.20 (overvalued). Cautious scenario kr 2.82, optimistic scenario kr 4.70. The calculation is refreshed regularly with new filings.
What is the revenue of Vivesto AB (VIVE)?
Vivesto AB reported trailing-twelve-month revenue of about 8.0K SEK (latest available figure, as of Nov 13, 2026).
What is the intrinsic value of Vivesto AB (VIVE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vivesto AB it is kr 3.76 per share (as of Nov 13, 2026), against a price of kr 7.20.
Is Vivesto AB stock overvalued or undervalued in 2026?
As of Nov 13, 2026, VIVE trades above its calculated fair value: price kr 7.20, fair value kr 3.76, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VIVE?
No. The price is what the market pays today (kr 7.20); the fair value is what the company's own numbers justify (kr 3.76). For Vivesto AB the two are kr 3.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vivesto AB worth?
The market values Vivesto AB at about 79.7M SEK (market capitalisation, as of Nov 13, 2026). Per share that is kr 7.20; our models calculate a fair value of kr 3.76 per share.
What do the bullish and bearish scenarios say about VIVE?
Our models span a range for Vivesto AB: cautious scenario kr 2.82, base kr 3.76, optimistic kr 4.70 per share (as of Nov 13, 2026, price kr 7.20). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vivesto AB (VIVE)?
Balance-sheet figures for Vivesto AB (as of Nov 13, 2026): return on equity −21.1%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is VIVE from its 52-week high?
Vivesto AB trades at kr 7.20, about 65% below its 52-week high of kr 20.63 and 6% above the low of kr 6.82 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 3.76 is for.
Which stocks are comparable to Vivesto AB?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vivesto AB stock attractive at the current price?
The data as of Nov 13, 2026: price kr 7.20, calculated fair value kr 3.76 (−48%), Quality Score 49/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8% above its aggregate fair value. Vivesto AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vivesto AB (VIVE)?
The closing price on Nov 13, 2026 was kr 7.20. Our estimate is kr 3.76, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vivesto AB right now?
The price sits above even our optimistic bull case (kr 4.70). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Vivesto AB

How large is the market capitalisation of Vivesto AB (VIVE)?
The market capitalisation of Vivesto AB is 79.7M SEK (≈ $7.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Vivesto AB (VIVE)?
Earnings per share at Vivesto AB are kr −4.12. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Vivesto AB (VIVE)?
The return on equity (ROE) of Vivesto AB is −21.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vivesto AB (VIVE)?
On an EBIT basis the return on assets of Vivesto AB is −46.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vivesto AB (VIVE)?
The operating margin of Vivesto AB is −393,313% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vivesto AB (VIVE)?
Revenue at Vivesto AB is growing 223% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Vivesto AB (VIVE) generate?
The free cash flow of Vivesto AB is −43.8M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vivesto AB (VIVE) carry?
The net debt of Vivesto AB is 11.0M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Vivesto AB in the live analysis

One click puts Vivesto AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.